Cargando…
Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report
BACKGROUND: Biologics dramatically improve symptoms of severe asthma; however, various exacerbating factors may induce flare-up. Pneumocystis spp. have not been reported as a cause of asthma exacerbation during biologic use, although patients with severe asthma have high levels of antibodies against...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035245/ https://www.ncbi.nlm.nih.gov/pubmed/35461263 http://dx.doi.org/10.1186/s13223-022-00678-y |
_version_ | 1784693255200309248 |
---|---|
author | Takeda, Kazuya Sumi, Toshiyuki Nagahisa, Yuta Matsuura, Keigo Sekikawa, Motoki Watanabe, Hiroki Yamada, Yuichi Chiba, Hirofumi |
author_facet | Takeda, Kazuya Sumi, Toshiyuki Nagahisa, Yuta Matsuura, Keigo Sekikawa, Motoki Watanabe, Hiroki Yamada, Yuichi Chiba, Hirofumi |
author_sort | Takeda, Kazuya |
collection | PubMed |
description | BACKGROUND: Biologics dramatically improve symptoms of severe asthma; however, various exacerbating factors may induce flare-up. Pneumocystis spp. have not been reported as a cause of asthma exacerbation during biologic use, although patients with severe asthma have high levels of antibodies against Pneumocystis spp. CASE PRESENTATION: An 87-year-old female with severe asthma that was well-controlled with mepolizumab, who developed a steroid-resistant refractory flare-up. Chest computed tomography showed bilateral ground glass opacities, and results of polymerase chain reaction tests on induced sputum were positive for Pneumocystis DNA. Therefore, a diagnosis of Pneumocystis pneumonia was made. The clinical symptoms improved after treatment with sulfamethoxazole–trimethoprim. CONCLUSION: Clinicians should be aware of Pneumocystis pneumonia as a cause of refractory exacerbation of bronchial asthma during use of interleukin-5 inhibitors. |
format | Online Article Text |
id | pubmed-9035245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90352452022-04-25 Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report Takeda, Kazuya Sumi, Toshiyuki Nagahisa, Yuta Matsuura, Keigo Sekikawa, Motoki Watanabe, Hiroki Yamada, Yuichi Chiba, Hirofumi Allergy Asthma Clin Immunol Case Report BACKGROUND: Biologics dramatically improve symptoms of severe asthma; however, various exacerbating factors may induce flare-up. Pneumocystis spp. have not been reported as a cause of asthma exacerbation during biologic use, although patients with severe asthma have high levels of antibodies against Pneumocystis spp. CASE PRESENTATION: An 87-year-old female with severe asthma that was well-controlled with mepolizumab, who developed a steroid-resistant refractory flare-up. Chest computed tomography showed bilateral ground glass opacities, and results of polymerase chain reaction tests on induced sputum were positive for Pneumocystis DNA. Therefore, a diagnosis of Pneumocystis pneumonia was made. The clinical symptoms improved after treatment with sulfamethoxazole–trimethoprim. CONCLUSION: Clinicians should be aware of Pneumocystis pneumonia as a cause of refractory exacerbation of bronchial asthma during use of interleukin-5 inhibitors. BioMed Central 2022-04-23 /pmc/articles/PMC9035245/ /pubmed/35461263 http://dx.doi.org/10.1186/s13223-022-00678-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Takeda, Kazuya Sumi, Toshiyuki Nagahisa, Yuta Matsuura, Keigo Sekikawa, Motoki Watanabe, Hiroki Yamada, Yuichi Chiba, Hirofumi Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report |
title | Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report |
title_full | Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report |
title_fullStr | Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report |
title_full_unstemmed | Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report |
title_short | Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report |
title_sort | refractory flare-up of severe bronchial asthma controlled with mepolizumab due to pneumocystis pneumonia: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035245/ https://www.ncbi.nlm.nih.gov/pubmed/35461263 http://dx.doi.org/10.1186/s13223-022-00678-y |
work_keys_str_mv | AT takedakazuya refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport AT sumitoshiyuki refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport AT nagahisayuta refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport AT matsuurakeigo refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport AT sekikawamotoki refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport AT watanabehiroki refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport AT yamadayuichi refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport AT chibahirofumi refractoryflareupofseverebronchialasthmacontrolledwithmepolizumabduetopneumocystispneumoniaacasereport |